Recruiting Colorectal Cancer Studies in Chicago
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective...
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (I...
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is gi...
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomiz...
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC)....
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
This phase II trial studies how well CBX-12 works in treating patients with microsatellite stable colorectal cancer that has spread to other parts of the body (metastatic) and is no longer responding ...
About Colorectal Cancer Clinical Trials in Chicago
Colorectal cancer starts in the colon or rectum and is the third most common cancer diagnosed in both men and women. Early detection through screening significantly improves outcomes. Treatments include surgery, chemotherapy, radiation, and targeted therapies.
There are currently 6 colorectal cancer clinical trials recruiting participants in Chicago, ILLINOIS. These studies are seeking a combined 1,860 participants. Research is being sponsored by GlaxoSmithKline, AbbVie, Ibrahim Halil Sahin and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Colorectal Cancer Clinical Trials in Chicago — FAQ
Are there colorectal cancer clinical trials in Chicago?
Yes, there are 6 colorectal cancer clinical trials currently recruiting in Chicago, ILLINOIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chicago?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.
Are clinical trials in Chicago free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.
What colorectal cancer treatments are being tested?
The 6 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for colorectal cancer.
Data updated March 2, 2026 from ClinicalTrials.gov